Long-term efficacy and safety of divozilimab during 2-year treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-4/MIRANTIBUS-Reference-Cited by-同舟云学术

Long-term efficacy and safety of divozilimab during 2-year treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-4/MIRANTIBUS

Published:2024 Issue:4 Volume:124 Page:86
ISSN:1997-7298
Container-title:S.S. Korsakov Journal of Neurology and Psychiatry
language:en
Short-container-title:S.S. Korsakov J. Neuro. Psych.

Author:

Boyko A.N.^ORCID,Alifirova V.M.^ORCID,Lukashevich I.G.^ORCID,Goncharova Z.A.^ORCID,Greshnova I.V.^ORCID,Zaslavsky L.G.^ORCID,Kotov S.V.^ORCID,Malkova N.A.^ORCID,Mishin G.N.^ORCID,Parshina E.V.^ORCID,Poverennova I.Ye.^ORCID,Prakhova L.N.^ORCID,Sivertseva S.A.^ORCID,Smagina I.V.^ORCID,Totolyan N.A.^ORCID,Trinitatsky Yu.V.^ORCID,Trushnikova T.N.^ORCID,Khabirov F.A.^ORCID,Chefranova J.Yu.^ORCID,Shchur S.G.^ORCID,Dudin V.A.^ORCID,Pokhabov D.V.^ORCID,Artemeva A.V.^ORCID,Eremeeva A.V.^ORCID,Linkova Yu.N.^ORCID,Zinkina-Orikhan A.V.^ORCID

Publisher

Media Sphere Publishing Group

Reference15 articles.

1. Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. Science. 2019;365(6460):232-327

2. The Multiple Sclerosis International Federation (MSIF). Atlas of MS, 3rd Edition: Mapping multiple sclerosis around the world key epidemiology findings, 2020. https://www.msif.org/wp-content/uploads/2020/10/Atlas-3rd-Edition-Epidemiology-report-EN-updated-30-9-20.pdf

3. Lassmann H, Brück W, Lucchinetti CF. The immunopathology of multiple sclerosis: an overview. Brain Pathol. 2007;17(2):210-218

4. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology. 1996;46(4):907-911

5. Clinical recommendations for the use of ocrelizumab in patients with multiple sclerosis

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Parenteral anti-B cell therapy for multiple sclerosis: From origins to the creation of the Russian drug divosilimab;Meditsinskiy sovet = Medical Council;2024-08-15

2. The first experience with the use of divozilimab in the treatment of multiple sclerosis patients in daily clinical practice;S.S. Korsakov Journal of Neurology and Psychiatry;2024